EPZM up +2.81% percent right now. $EPZM High is at
Post# of 88906
Posted On: 11/11/2014 3:32:04 PM
EPZM up +2.81% percent right now. $EPZM High is at 24.61 and the Low 23.81 with current volume of 104,471.
Recent News posted below.
EPZM Epizyme Inc Recent Headline News
Nasdaq stocks posting largest percentage decreases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
HTBX: 4.80 (-0.18), TNGO: 12.84 (+0.44), ENPH: 10.45 (-0.78), PRSC: 37.62 (-0.26), MTRX: 23.17 (+0.42), EPZM: 23.95 (+0.08), CHUY: 22.52 (-0.74), AMRI: 17.55 (+0.45), ANDE: 54.79 (+0.02), SNMX: 5.95 (-0.06), ZU: 29.11 (+0.28)
Epizyme drops after cancer drug data underwhelms
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 11:35AM CST
EPZM: 23.95 (+0.08)
Epizyme (EPZM) CEO Robert Gould on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:18AM CST
EPZM: 23.95 (+0.08)
Epizyme Shares Weak on Disappointing Leukemia Drug Study Results
at The Street - Thu Nov 06, 10:12AM CST
New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.
EPZM: 23.95 (+0.08)
Epizyme misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:56AM CST
EPZM: 23.95 (+0.08)
Epizyme Announces Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 6:32AM CST
--EPZ-6438 Phase 1 trial for pediatric patients with INI1-deficient tumors expected to initiate in 1H15 and Phase 2 trial for adult patients with INI1-deficient tumors expected to initiate in 2015
EPZM: 23.95 (+0.08)
Epizyme Reports Publication of Preliminary Findings from Phase 1 Study of DOT1L Inhibitor EPZ-5676 in ASH Annual Meeting Abstract
Business Wire - Thu Nov 06, 6:32AM CST
--Adverse events were predominantly Grade 1 or Grade 2 in severity
EPZM: 23.95 (+0.08)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 108.47 (+1.45), CLVS: 60.74 (+0.60), ARWR: 6.41 (+0.20), ACHN: 12.50 (-0.35), MRK: 59.36 (+0.55), RTRX: 11.20 (+0.46), RGLS: 20.28 (-0.63), EPZM: 23.95 (+0.08), AGIO: 82.28 (+0.50), RMTI: 11.10 (+0.20), ARNA: 4.50 (+0.10), KERX: 15.84 (-0.59)
Epizyme to Report Third Quarter 2014 Financial Results and Provide Corporate Update on November 6, 2014
Business Wire - Thu Oct 30, 7:02AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, November 6, 2014, at 8:00 a.m. ET to report third quarter 2014 financial results and provide a corporate update.
EPZM: 23.95 (+0.08)
Epizyme CMO quits
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 9:44AM CDT
EPZM: 23.95 (+0.08)
Epizyme Announces Departure of Chief Medical Officer Eric Hedrick, M.D.
Business Wire - Mon Oct 27, 7:01AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Chief Medical Officer Eric Hedrick, M.D., has resigned from the Company, effective October 31, 2014. Dr. Hedrick has agreed to assist Epizyme in an advisory capacity through the end of 2014. Peter Ho, M.D., Ph.D., who joined the company in September as Chief Development Officer, will continue to oversee the Company's clinical development, regulatory and translational medicine functions.
EPZM: 23.95 (+0.08)
Can Epizyme (EPZM) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 2:48PM CDT
Epizyme, Inc. (EPZM) has an earnings ESP of 0.00% and a Zacks Rank #3 (Hold).
ACT: 243.41 (-2.32), LGND: 57.01 (+1.33), TEVA: 58.32 (+0.28), EPZM: 23.95 (+0.08)
Epizyme Announces Notices of Allowance for US Patent Applications Covering PRMT5 Inhibitors and Methods of Cancer Treatment with PRMT5 Inhibitors
Business Wire - Thu Oct 23, 7:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the US Patent and Trademark Office has granted Notices of Allowance for US Patent Applications, Nos. 14/136,551 and 14/136,738, both entitled "PRMT5 Inhibitors and Uses Thereof." The allowed claims cover inhibitors of PRMT5 and methods of cancer treatment with PRMT5 inhibitors. PRMT5 is implicated in several cancers, including blood cancers.
EPZM: 23.95 (+0.08)
What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 8.89 (-0.43), EBS: 24.30 (+0.35), ENZ: 4.94 (-0.10), EPZM: 23.95 (+0.08)
Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma
Business Wire - Fri Oct 17, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today presented pre-clinical data on EPZ-6438 (E7438), its oral, small molecule inhibitor of EZH2, in models of synovial sarcoma, a soft tissue sarcoma that typically affects young adults. Synovial sarcomas are characterized by a translocation of chromosomes X and 18, generating an SS18-SSX fusion protein that creates a state of deficiency of the INI1 protein. The data were presented by Heike Keilhack, Ph.D., Director of Biological Sciences, Epizyme, during the annual meeting of the Connective Tissue Oncology Society, held October 15-18 in Berlin, Germany. The poster is available on the Epizyme website at http://www.epizyme.com/wp-content/uploads/201...Poster.pdf.
EPZM: 23.95 (+0.08)
Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:18AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 7% on the day.
EBS: 24.30 (+0.35), FCSC: 2.68 (-0.12), PLX: 1.95 (-0.10), EPZM: 23.95 (+0.08)
Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:04AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) was a big mover last session, as the company saw its shares rise almost 19% on the day.
EBS: 24.30 (+0.35), ALNY: 98.74 (-0.44), FCSC: 2.68 (-0.12), EPZM: 23.95 (+0.08)
Vical Incorporated (VICL) in Focus: Stock Soars 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 7:43AM CDT
Vical Incorporated (VICL) was a big mover last session, as the company saw its shares rise 12% on the day.
VICL: 1.13 (-0.03), EBS: 24.30 (+0.35), FCSC: 2.68 (-0.12), EPZM: 23.95 (+0.08)
Epizyme Announces Clinical and Pre-Clinical Data to be Featured in Oral and Poster Presentations at American Society of Hematology (ASH) Annual Meeting
Business Wire - Fri Oct 10, 7:00AM CDT
-- Oral presentation of pre-clinical data on first-in-class PRMT5 inhibitor in lymphoma models -
EPZM: 23.95 (+0.08)
Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium
Business Wire - Wed Oct 01, 6:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced, in conjunction with its development partner Eisai, that clinical data from the ongoing Phase 1 study of EPZ-6438 (E7438), an oral, small molecule inhibitor of EZH2, will be featured in a late-breaking oral presentation at the 26th EORTC-AACR-NCI Symposium on Molecular Targets and Cancer Therapeutics, to be held November 18-21 in Barcelona, Spain. The presentation will take place during the plenary session on Epigenetic Targets. In addition, this session will feature a presentation from Chief Scientific Officer Robert Copeland, Ph.D., discussing Epizyme's targeted therapies against the histone methyltransferases (HMTs) DOT1L and EZH2.
EPZM: 23.95 (+0.08)
Recent News posted below.
EPZM Epizyme Inc Recent Headline News
Nasdaq stocks posting largest percentage decreases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
HTBX: 4.80 (-0.18), TNGO: 12.84 (+0.44), ENPH: 10.45 (-0.78), PRSC: 37.62 (-0.26), MTRX: 23.17 (+0.42), EPZM: 23.95 (+0.08), CHUY: 22.52 (-0.74), AMRI: 17.55 (+0.45), ANDE: 54.79 (+0.02), SNMX: 5.95 (-0.06), ZU: 29.11 (+0.28)
Epizyme drops after cancer drug data underwhelms
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 11:35AM CST
EPZM: 23.95 (+0.08)
Epizyme (EPZM) CEO Robert Gould on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:18AM CST
EPZM: 23.95 (+0.08)
Epizyme Shares Weak on Disappointing Leukemia Drug Study Results
at The Street - Thu Nov 06, 10:12AM CST
New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.
EPZM: 23.95 (+0.08)
Epizyme misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:56AM CST
EPZM: 23.95 (+0.08)
Epizyme Announces Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 6:32AM CST
--EPZ-6438 Phase 1 trial for pediatric patients with INI1-deficient tumors expected to initiate in 1H15 and Phase 2 trial for adult patients with INI1-deficient tumors expected to initiate in 2015
EPZM: 23.95 (+0.08)
Epizyme Reports Publication of Preliminary Findings from Phase 1 Study of DOT1L Inhibitor EPZ-5676 in ASH Annual Meeting Abstract
Business Wire - Thu Nov 06, 6:32AM CST
--Adverse events were predominantly Grade 1 or Grade 2 in severity
EPZM: 23.95 (+0.08)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 108.47 (+1.45), CLVS: 60.74 (+0.60), ARWR: 6.41 (+0.20), ACHN: 12.50 (-0.35), MRK: 59.36 (+0.55), RTRX: 11.20 (+0.46), RGLS: 20.28 (-0.63), EPZM: 23.95 (+0.08), AGIO: 82.28 (+0.50), RMTI: 11.10 (+0.20), ARNA: 4.50 (+0.10), KERX: 15.84 (-0.59)
Epizyme to Report Third Quarter 2014 Financial Results and Provide Corporate Update on November 6, 2014
Business Wire - Thu Oct 30, 7:02AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, November 6, 2014, at 8:00 a.m. ET to report third quarter 2014 financial results and provide a corporate update.
EPZM: 23.95 (+0.08)
Epizyme CMO quits
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 9:44AM CDT
EPZM: 23.95 (+0.08)
Epizyme Announces Departure of Chief Medical Officer Eric Hedrick, M.D.
Business Wire - Mon Oct 27, 7:01AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Chief Medical Officer Eric Hedrick, M.D., has resigned from the Company, effective October 31, 2014. Dr. Hedrick has agreed to assist Epizyme in an advisory capacity through the end of 2014. Peter Ho, M.D., Ph.D., who joined the company in September as Chief Development Officer, will continue to oversee the Company's clinical development, regulatory and translational medicine functions.
EPZM: 23.95 (+0.08)
Can Epizyme (EPZM) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 2:48PM CDT
Epizyme, Inc. (EPZM) has an earnings ESP of 0.00% and a Zacks Rank #3 (Hold).
ACT: 243.41 (-2.32), LGND: 57.01 (+1.33), TEVA: 58.32 (+0.28), EPZM: 23.95 (+0.08)
Epizyme Announces Notices of Allowance for US Patent Applications Covering PRMT5 Inhibitors and Methods of Cancer Treatment with PRMT5 Inhibitors
Business Wire - Thu Oct 23, 7:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the US Patent and Trademark Office has granted Notices of Allowance for US Patent Applications, Nos. 14/136,551 and 14/136,738, both entitled "PRMT5 Inhibitors and Uses Thereof." The allowed claims cover inhibitors of PRMT5 and methods of cancer treatment with PRMT5 inhibitors. PRMT5 is implicated in several cancers, including blood cancers.
EPZM: 23.95 (+0.08)
What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 8.89 (-0.43), EBS: 24.30 (+0.35), ENZ: 4.94 (-0.10), EPZM: 23.95 (+0.08)
Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma
Business Wire - Fri Oct 17, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today presented pre-clinical data on EPZ-6438 (E7438), its oral, small molecule inhibitor of EZH2, in models of synovial sarcoma, a soft tissue sarcoma that typically affects young adults. Synovial sarcomas are characterized by a translocation of chromosomes X and 18, generating an SS18-SSX fusion protein that creates a state of deficiency of the INI1 protein. The data were presented by Heike Keilhack, Ph.D., Director of Biological Sciences, Epizyme, during the annual meeting of the Connective Tissue Oncology Society, held October 15-18 in Berlin, Germany. The poster is available on the Epizyme website at http://www.epizyme.com/wp-content/uploads/201...Poster.pdf.
EPZM: 23.95 (+0.08)
Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:18AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 7% on the day.
EBS: 24.30 (+0.35), FCSC: 2.68 (-0.12), PLX: 1.95 (-0.10), EPZM: 23.95 (+0.08)
Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:04AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) was a big mover last session, as the company saw its shares rise almost 19% on the day.
EBS: 24.30 (+0.35), ALNY: 98.74 (-0.44), FCSC: 2.68 (-0.12), EPZM: 23.95 (+0.08)
Vical Incorporated (VICL) in Focus: Stock Soars 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 7:43AM CDT
Vical Incorporated (VICL) was a big mover last session, as the company saw its shares rise 12% on the day.
VICL: 1.13 (-0.03), EBS: 24.30 (+0.35), FCSC: 2.68 (-0.12), EPZM: 23.95 (+0.08)
Epizyme Announces Clinical and Pre-Clinical Data to be Featured in Oral and Poster Presentations at American Society of Hematology (ASH) Annual Meeting
Business Wire - Fri Oct 10, 7:00AM CDT
-- Oral presentation of pre-clinical data on first-in-class PRMT5 inhibitor in lymphoma models -
EPZM: 23.95 (+0.08)
Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium
Business Wire - Wed Oct 01, 6:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced, in conjunction with its development partner Eisai, that clinical data from the ongoing Phase 1 study of EPZ-6438 (E7438), an oral, small molecule inhibitor of EZH2, will be featured in a late-breaking oral presentation at the 26th EORTC-AACR-NCI Symposium on Molecular Targets and Cancer Therapeutics, to be held November 18-21 in Barcelona, Spain. The presentation will take place during the plenary session on Epigenetic Targets. In addition, this session will feature a presentation from Chief Scientific Officer Robert Copeland, Ph.D., discussing Epizyme's targeted therapies against the histone methyltransferases (HMTs) DOT1L and EZH2.
EPZM: 23.95 (+0.08)
(0)
(0)Scroll down for more posts ▼